ReviewFrontiers in oncology2026
The mechanism of lncRNA PVT1 in oral squamous cell carcinoma.
Review in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oral squamous cell carcinoma, a common malignancy of the head and neck, is characterized by high rates of recurrence, metastasis, and chemoresistance, contributing to its persistently low five-year survival rate. Long non-coding RNA Plasmacytoma Variant Translocation 1(lncRNA PVT1), a significant oncogenic non-coding RNA, is frequently overexpressed in various human malignancies. Accumulating evidence highlights the central contribution of lncRNA PVT1 to OSCC pathogenesis through its regulation of essential oncogenic phenotypes, such as cell proliferation, invasion, metastatic dissemination, immune evasion, and chemoresistance. This review systematically summarizes the expression profile, functional mechanisms, and clinical significance of lncRNA PVT1 in OSCC, with a specific focus on molecular pathways such as the competitive endogenous RNA mechanism, induction of epithelial-mesenchymal transition, modulation of key signaling pathways, and upstream regulation by m6A methylation. Furthermore, the potential of lncRNA PVT1 as a novel diagnostic biomarker and therapeutic target is discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.